CRS was G1 or G2 and responded to tocilizumab. Considering the CRS-related toxicities and the ADA formation, the Sponsor decided to halt dose escalation. No recommended phase 2 dose was determined.
10 months ago
Clinical • Metastases
|
HLA-G (Major Histocompatibility Complex, Class I, G)